thalidomide has been researched along with Bronchial Hyperreactivity in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Bronchial Hyperreactivity: Tendency of the smooth muscle of the tracheobronchial tree to contract more intensely in response to a given stimulus than it does in the response seen in normal individuals. This condition is present in virtually all symptomatic patients with asthma. The most prominent manifestation of this smooth muscle contraction is a decrease in airway caliber that can be readily measured in the pulmonary function laboratory.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study is designed to determine the effect and the potential mechanism of thalidomide in the pathogenesis of asthmatic airways using animal model of allergic asthma." | 7.81 | Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide. ( Chang, YS; Cho, SH; Kang, HR; Kim, HR; Kim, HY; Kwon, HS; Lee, HS; Min, KU; Park, DE; Woo, YD, 2015) |
| "When thalidomide was administered to OVA-challenged mice, the number of eosinophils in bronchoalveolar lavage fluid (BALF) was significantly decreased." | 5.36 | Thalidomide attenuates airway hyperresponsiveness and eosinophilic inflammation in a murine model of allergic asthma. ( Asano, T; Hasegawa, Y; Ito, S; Kume, H; Taki, F, 2010) |
| "This study is designed to determine the effect and the potential mechanism of thalidomide in the pathogenesis of asthmatic airways using animal model of allergic asthma." | 3.81 | Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide. ( Chang, YS; Cho, SH; Kang, HR; Kim, HR; Kim, HY; Kwon, HS; Lee, HS; Min, KU; Park, DE; Woo, YD, 2015) |
| "When thalidomide was administered to OVA-challenged mice, the number of eosinophils in bronchoalveolar lavage fluid (BALF) was significantly decreased." | 1.36 | Thalidomide attenuates airway hyperresponsiveness and eosinophilic inflammation in a murine model of allergic asthma. ( Asano, T; Hasegawa, Y; Ito, S; Kume, H; Taki, F, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, HS | 1 |
| Kwon, HS | 1 |
| Park, DE | 1 |
| Woo, YD | 1 |
| Kim, HY | 1 |
| Kim, HR | 1 |
| Cho, SH | 1 |
| Min, KU | 1 |
| Kang, HR | 1 |
| Chang, YS | 1 |
| Asano, T | 1 |
| Kume, H | 1 |
| Taki, F | 1 |
| Ito, S | 1 |
| Hasegawa, Y | 1 |
2 other studies available for thalidomide and Bronchial Hyperreactivity
| Article | Year |
|---|---|
Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide.
Topics: Allergens; Alum Compounds; Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchi | 2015 |
Thalidomide attenuates airway hyperresponsiveness and eosinophilic inflammation in a murine model of allergic asthma.
Topics: Animals; Anti-Inflammatory Agents; Asthma; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; | 2010 |